[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hla-class-i-histocompatibility-antigen-a-2-alpha-chain":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HLA Class I Histocompatibility Antigen, A-2 Alpha Chain",14,13,[8,16,22,29,36,43,49,55,61,67,73,79,85,91],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05989828","A2-ESO-1 TCR-Engineered T Cells for Relapsed\u002FRefractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:16:21.385056Z","2026-05-29T15:36:40.167133Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT02870244","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes",[12],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.498267Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05127824","Autologous Dendritic Cell Vaccine in Kidney Cancer",[26],"Phase 2","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.873624Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06472245","Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor",[33],"Phase 3","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.715403Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT04669171","A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",[40],"Phase 1\u002FPhase 2","2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.101658Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT02358187","A Vaccine Trial for Low Grade Gliomas",[26],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:27.663670Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05232916","Phase 3 Study to Evaluate the Efficacy and Safety of HER2\u002FNeu Peptide GLSI-100 (GP2 + GM-CSF) in HER2\u002FNeu Positive Subjects",[33],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.514719Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04634357","ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma",[40],"2026-08-26T02:17:21.315591Z","2026-07-19T19:36:05.119597Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06644755","First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:27.064259Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",[40],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:26.963212Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06682793","A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",[40],"2026-08-26T02:14:59.425132Z","2026-05-05T02:43:26.900916Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05642455","SPEARHEAD-3 Pediatric Study",[40],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.852369Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.276659Z",{"nct_id":92,"title":93,"phases":94,"status":95,"updated_at":96,"content_modified":97},"NCT07414979","Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:54.044282Z","2026-05-05T02:43:27.425497Z"]